Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings
Regeneron expects Q3 EPS of $16.19 and revenue of $4.56B; extended BARDA’s Inmazeb supply deal as analysts raise price targets.
Share
Why It Matters
Regeneron told people what money it will make this quarter. Experts think the company is doing well and raised their price guesses.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.